Abstract
Immunizations belong to the most successful interventions in medicine. Like other drugs, vaccines undergo long periods of pre-clinical development, followed by careful clinical testing through study Phases I, II, and III before they receive licensure. A successful candidate vaccine will move on to be an investigational vaccine to undergo three phases of pre-licensure clinical trials in a stepwise fashion before it can be considered for approval, followed by an optional fourth phase of post-marketing assessment. The overall risk–benefit assessment of a candidate vaccine is very critical in making the licensure decision for regulatory authorities, supported by their scientific committees. It includes analyses of immunogenicity, efficacy, reactogenicity or tolerability, and safety of the vaccine. Public trust in vaccines is a key to the success of immunization programs worldwide. Maintaining this trust requires knowledge of the benefits and scientific understanding of real or perceived risks of immunizations. Under certain circumstances, pre- or post-exposure passive immunization can be achieved by administration of immunoglobulines. In terms of prevention of infectious diseases, disinfection can be applied to reduce the risk of transmission of pathogens from patient to patient, health-care workers to patients, patients to health-care workers, and objects or medical devices to patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdulla S, Oberholzer R, Juma O et al (2008) Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. N Engl J Med 359:2533–2544
American Academy of Pediatrics (2009) Passive immunization. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS (eds) Red book: 2009 report of the committee on infectious diseases, 28th edn. American Academy of Pediatrics, Elk Grove Village, IL
Black SB, Lewis E, Shinefield HR et al (2002) Lack of association between receipt of conjugate haemophilus influenzae type B vaccine (HbOC) in infancy and risk of type 1 (juvenile onset) diabetes: long term follow-up of the HbOC efficacy trial cohort. Pediatr Infect Dis J 21:568–569
Boland G, Beran J, Lievens M et al (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23:316–320
Bonhoeffer J, Kohl K, Chen R et al (2002) The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21:298–302
Centers for Disease Control and Prevention (CDC) (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction–eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 57:144–148
Cooper CL, Davis HL, Morris ML et al (2004) CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24:693–701
De Stefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C (2004) Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 113:259–266
De Wals P, Deceuninck G, Boulianne N, De Serres G (2004) Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292:2491–2494
Dettenkofer M, Daschner F (1997) Umweltschonende Sterilisation und Desinfektion. In: Daschner F (ed) Praktische Krankenhaushygiene und Umweltschutz, 1st edn. Springer, Heidelberg
Didierlaurent AM, Morel S, Lockman L et al (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183:6186–6197
Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27(Suppl 4):D65–D68
Gessner BD, Adegbola RA (2008) The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines. Vaccine 26(Suppl 2):B3–B8
Giannini SL, Hanon E, Moris P et al (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937–5949
Grüber C, Illi S, Lau S et al (2003) Transient suppression of atopy in early childhood is associated with high vaccination coverage. Pediatrics 111:e282–e288
Guillaume L, Bath PA (2008) A content analysis of mass media sources in relation to the MMR vaccine scare. Health Inform J 14:323–334
Heininger U (2003) Prävention von Pneumokokkeninfektionen. Monatsschr Kinderheilkd 151:391–396
Heininger U (2004) The success of immunization – shoveling its own grave? Vaccine 22:2071–2072
Hocine MN, Farrington CP, Touzé E et al (2007) Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 25:5938–5943
Ioannidis JPA, Lau J (2001) Completeness of safety reporting in randomized trials. An evaluation of 7 medical areas. JAMA 285:437–443
Keitel W, Groth N, Lattanzi M et al (2010) Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28:840–848
Kohl KS, Gidudu J, Bonhoeffer J et al (2007) The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 25:5671–5674
Kombo LA, Gerber MA, Pickering LK et al (2001) Intussusception, infection, and immunization: summary of a workshop on rotavirus. Pediatrics 108(2):E37
Mutsch M, Zhou W, Rhodes P et al (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 350:896–903
Pichichero ME (2008) Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 4:262–270
Ruiz-Palacios GM, Guerrero ML, Bautista-Márquez A et al (2007) Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics 120:e253–e261
Sacarlal J, Aide P, Aponte JJ et al (2009) Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J Infect Dis 200:329–336
Sagara I, Ellis RD, Dicko A (2009) A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 27:7292–7298
Stehr K, Cherry JD, Heininger U et al (1998) A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine or DT vaccine. Pediatrics 101:1–11
Stratton KR, Howe CJ, Johnston RB Jr (1994) Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 271:1602–1605
Tapiainen T, Bar G, Bonhoeffer J, Heininger U (2006) Evaluation of the Brighton Collaboration case definition of acute intussusception during active surveillance. Vaccine 24:1483–1487
Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M (2009) MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291–6295
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heininger, U. (2011). Preventive Medicines. In: Seyberth, H., Rane, A., Schwab, M. (eds) Pediatric Clinical Pharmacology. Handbook of Experimental Pharmacology, vol 205. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20195-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-20195-0_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20194-3
Online ISBN: 978-3-642-20195-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)